Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching, Journal of Chromatography A, vol.692, issue.1-2, pp.45-52, 1995. ,
DOI : 10.1016/0021-9673(94)00608-C
Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus., Antimicrobial Agents and Chemotherapy, vol.33, issue.10, pp.1801-1804, 1989. ,
DOI : 10.1128/AAC.33.10.1801
First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results, HIV Medicine, vol.14, issue.17, pp.277-82, 2002. ,
DOI : 10.1097/00002030-200006160-00015
Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily, HIV Medicine, vol.29, issue.1, pp.1-6, 2005. ,
DOI : 10.1097/00002030-200210180-00019
Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.37, issue.3, pp.1358-66, 2004. ,
DOI : 10.1097/00126334-200411010-00004
High indinavir C is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen min, J Acquir ,
A Retrospective, Cohort-Based Survey of Patients Using Twice-Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and Efficacy, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.26, issue.3, pp.218-242, 2001. ,
DOI : 10.1097/00126334-200103010-00003
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load, AIDS, vol.17, issue.6, pp.831-871, 2003. ,
DOI : 10.1097/00002030-200304110-00008
Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients, Journal of Antimicrobial Chemotherapy, vol.51, issue.5, pp.1231-1239, 2003. ,
DOI : 10.1093/jac/dkg198
Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients, HIV Medicine, vol.14, issue.4, pp.307-320, 2004. ,
DOI : 10.1097/00002030-199910010-00001
Incidence and risk factors for the development of indinavir-associated renal complications, Journal of Antimicrobial Chemotherapy, vol.48, issue.3, pp.355-60, 2001. ,
DOI : 10.1093/jac/48.3.355
Risk Factors for Urological Symptoms in a Cohort of Users of the HIV Protease Inhibitor Indinavir Sulfate<subtitle>The ATHENA Cohort</subtitle>, Archives of Internal Medicine, vol.162, issue.13, pp.1493-501, 2002. ,
DOI : 10.1001/archinte.162.13.1493
Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans, Drug Metab Dispos, vol.24, pp.1389-94, 1996. ,
Urinary pH in HIV-infected adults in Ivory Coast and in France, AIDS, vol.17, issue.13, pp.2003-2008, 2003. ,
DOI : 10.1097/00002030-200309050-00028
Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients, British Journal of Clinical Pharmacology, vol.24, issue.3, pp.276-86, 2005. ,
DOI : 10.1067/mcp.2002.121424
Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence, Drug Metab Dispos, vol.24, pp.1298-306, 1996. ,
Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir, American Journal of Kidney Diseases, vol.36, issue.3, pp.507-522, 2000. ,
DOI : 10.1053/ajkd.2000.9791
Indinavir, Zidovudine, Lamivudine: 3-Year Follow-up, Annals of Internal Medicine, vol.134, issue.2, p.165, 2001. ,
DOI : 10.7326/0003-4819-134-2-200101160-00019
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients, AIDS, vol.17, issue.2, pp.209-223, 2003. ,
DOI : 10.1097/00002030-200301240-00011
Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals, Antivir Ther, vol.8, pp.603-612, 2003. ,